Keros Therapeutics, Inc.
KROS
$11.34
$0.312.81%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -97.30% | -21.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -97.30% | -21.50% | |||
| Cost of Revenue | -8.75% | -55.13% | |||
| Gross Profit | -231.50% | 79.25% | |||
| SG&A Expenses | 15.96% | -30.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.31% | -48.87% | |||
| Operating Income | -89.61% | 61.36% | |||
| Income Before Tax | -186.94% | 73.56% | |||
| Income Tax Expenses | -6.32% | 35.91% | |||
| Earnings from Continuing Operations | -222.27% | 76.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -222.27% | 76.28% | |||
| EBIT | -89.61% | 61.36% | |||
| EBITDA | -91.94% | 62.00% | |||
| EPS Basic | -381.36% | 76.29% | |||
| Normalized Basic EPS | -326.89% | 73.57% | |||
| EPS Diluted | -379.22% | 76.32% | |||
| Normalized Diluted EPS | -326.89% | 73.57% | |||
| Average Basic Shares Outstanding | -33.05% | 0.03% | |||
| Average Diluted Shares Outstanding | -33.05% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||